| Literature DB >> 30689588 |
Dominik Özbe1, Elmar Graessel1, Carolin Donath1, Anna Pendergrass1.
Abstract
BACKGROUND: There is no curative medical treatment for dementia. Therefore, researchers turned their attention to non-pharmacological treatment approaches. Many reviews analyzed the efficacy of single-component interventions, but there has been no systematic review of multicomponent interventions so far.Entities:
Keywords: Behavioral symptoms; cognitive dysfunction; dementia; multicomponent intervention; review
Mesh:
Year: 2019 PMID: 30689588 PMCID: PMC6398841 DOI: 10.3233/JAD-180980
Source DB: PubMed Journal: J Alzheimers Dis ISSN: 1387-2877 Impact factor: 4.472
PubMed search terms
| “dementia” [MeSH Terms] OR dement* OR alz* OR alzheimer OR “lewy body” OR “memory impairment” OR “memory disorder” OR “cognitive impairment” OR “cognitive disorder” OR “memory dysfunction” OR “cognitive dysfunction” OR “mild cognitive impairment” OR “MCI” | |
| AND | Combine OR combined OR combining OR combination OR multidisciplinary OR multi#disciplinary OR multicomponent OR multi#component OR multimodal OR multi#modal OR multifaceted OR multi#faceted OR multidimensional OR multi#dimensional OR multiple OR adjunction OR adjunctive OR interdisciplinary OR cross-disciplinary OR multifactorial OR multi#factorial |
| AND | therapy OR therapies OR intervention OR interventions OR treatment OR treatments OR training OR “cognitive training” OR “cognitive support” |
| AND | "Randomized Controlled Trial” [Publication Type] OR “Randomized Controlled Trials as Topic"[Mesh] OR “rct” OR controlled trial OR control trial OR randomized controlled trial OR randomised controlled trial OR randomized control trial OR randomised control trial |
Notes. Not specified terms were searched in title or abstract.
Fig.1PRISMA flow chart.
Overview of the included studies
| Source | Country | Setting | Diagnosis | Sample n (IG/CG) | Age (IG/CG) | Baseline MMSE (IG/CG) | Intervention | Control | Measures | Antidementia Medication |
| Schwenk et al. [ | Germany | community-dwelling geriatric hospital | dementia | 61 (26/35) | 80.4/ 82.3 | 21.0/ 21.7 | progressive resistance and balance training + dual-task training | supervised motor placebo group training |
| yes, but no mention of specific medication |
| Suzuki et al. [ | Japan | community-dwelling no exact location reported | MCI (Petersen) | 100 (50/50) | 74.8/ 75.8 | 26.8/ 26.3 | muscle strength exercises and aerobic exercise + dual-task training | education control group | adverse events | exclusion of donepezil users |
| Maci et al. [ | Italy | home-dwelling gymnasium | probable or possible AD | 14 (7/7) | 75.0/ 70.3 | 17.5/ 18.2 | balance, strength and psychomotor exercises + cognitive stimulation | no intervention |
| exclusion: current use of medication for cognitive enhancement (e.g., ginkgo biloba) other than cholinesterase inhibitors or memantine as previously described |
| Rapp, Brenes &Marsh [ | USA | community-dwelling no exact location reported | MCI (Petersen) | 19 (9/10) | 73.3/75.1 | 28.0/ 27.3 | relaxation skill + psychoeducation and memory skills | no treatment |
| excluded if they were taking medications (e.g., donepezil, antidepressants) or herbal mixtures (e.g., gingko biloba) likely to affect cognitive function |
| Troyer et al. [ | Canada | home-dwelling no exact location reported | MCI (Petersen) | 48 (24/24) | 76.0/ 74.8 | 27.2/ 28.5 | relaxation skill + psychoeducation and memory skills | waitlist-control group |
| nothing concerning medication reported |
| Buschert et al. [ | Germany | home-dwelling memory clinic |
| 39 (20/19) |
|
| cognitive training and psychoeducation + psychomotor exercises | 6 monthly sessions with paper-pencil exercises for isolated cognitive functions, after 6 months cross/over to treatment |
| subjects were, if treated, on stable medication of antidementia drugs for at least three months prior to the start of the study, |
| Olazaran et al. [ | Spain | community-dwelling day-care center | clinical diagnosis of MCI &probable AD | 84 (44/40) | 75.3/ 73.4 | 17.6/ 17.4 | reality orientation and cognitive exercises + ADL-training + psychomotor exercises | no intervention | adverse events | current use of a daily dose of 5 to 10 mg of donepezil or 6 to 12 mg of rivastigmine for more than 1 month, |
| Source | Country | Setting | Diagnosis | Sample | Age | Baseline | Intervention | Control | Measures | Antidementia |
| n (IG/CG) | (IG/CG) | MMSE (IG/CG) | Medication | |||||||
| Graessel et al. [ | Germany | nursing home | primary degenerative dementia | 96 (50/46) | 84.5/ 85.7 | 15.4/ 13.8 | cognitive training + ADL-training + psychomotor exercises | standard care | adverse events | Only 13 patients (13.5%) were taking anti-dementia medication at baseline (equally distributed in intervention and control group) |
| Baglio et al. [ | Italy | community-dwelling care dyads no exact location reported | probable AD | 52 (28/24) | 75.6/ 76.5 | 21.5/ 22.0 | cognitive stimulation + physical activity + ADL-training + recreational activities | waitlist-control group with standard treatment of care |
| Excluded: recent (3 months before the MST) introduction or dose modification of the following pharmacological treatments: cholinesterase inhibitor, memantine |
ADAS-Cog, Alzheimer’s Disease Assessment Scale - Cognitive Subscale; AES, Apathy Evaluation Scale; CBS-QoLD, Cornell-Brown Scale for Quality of Life in Dementia; CDR, Clinical Dementia Rating; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; CG, control group; CSDD, Cornell Scale for Depression in Dementia; E-ADL, Erlangen Test of Activities of Daily Living; FAB, Frontal Assessment Battery; FAQ, Functional Activities Questionnaire; FLSA, Functional Living Skills Assessment Scale; fMRI, functional magnetic resonance imaging; GDS-15, Geriatric Depression Scale- 15 item short form; HAM-A, Hamilton Anxiety Rating Scale; IADL, Instrumental Activities of Daily Living Scale; IG, intervention group; MADRS, Montgomery– Åsberg Depression Rating Scale; MCI, mild cognitive impairment; MFQ, Memory Functioning Questionnaire; MMSE, Mini-Mental Status Examination; MMQ, Multifactorial Metamemory Questionnaire; MRI, magnetic resonance imaging; NPI, Neuropsychiatric Inventory; QOL-AD, Quality of Life-Alzheimer’s disease; RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; SF-36, Short Form 36 health survey questionnaire; TMT, Trail Making Test; WMS-LM I & I, Wechsler Memory Scale - Logical Memory I & II.
Fig.2Overview of used components and intervention effects on different outcome domains. Purple = component used; red = IG has the same or worse values than CG; green = at least one measure in this domain shows an advantage for the IG.
Fig.3Overview of intervention protocol, total intervention time and group size in conjunction with the intervention effects. Red = IG has the same or worse values than CG; green = at least one measure in this domain shows an advantage for the IG; *the total intervention time was calculated with 40 reported sessions; ** the intervention had 10 sessions held as following: the first 7 sessions took place in 7 weeks followed by 3 review sessions: 1st after 2 weeks; 2nd after additional 4 weeks, 3rd after additional 12 weeks; for the total intervention time calculation 180 min testing were subtracted; *** the total intervention time was calculated with 103 reported sessions.
Table 3Risk of bias assessment of the included studies